- Home
- NEGG vs ZURA Comparison
NEGG vs ZURA Comparison
Compare NEGG & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEGG | ZURA |
|---|---|---|
| Founded | 2001 | 2022 |
| Country | United States | United States |
| Employees | 762 | 30 |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.1M | 521.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEGG | ZURA |
|---|---|---|
| Price | $38.03 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 43.1K | ★ 505.3K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.99 |
| 52 Week High | $137.84 | $7.25 |
Technical Indicators
Market Signals| Indicator | NEGG | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 49.27 |
| Support Level | $30.58 | $5.49 |
| Resistance Level | $56.73 | $6.99 |
| Average True Range (ATR) | 3.97 | 0.48 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 41.43 | 59.42 |
Price Performance
Historical ComparisonAbout NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.